Zu-Yau Lin

List of Publications by Year
in descending order

130	2,393	236833	265120
papers	citations	25 h-index	42 g-index

132	132	132	2734
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high <scp>NANOG</scp> expression. Kaohsiung Journal of Medical Sciences, 2022, 38, 157-164.	0.8	1
2	Serum Wisteria floribunda <scp>agglutininâ€positive Macâ€2â€binding</scp> protein expression predicts disease severity in nonalcoholic steatohepatitis patients. Kaohsiung Journal of Medical Sciences, 2022, 38, 261-267.	0.8	2
3	Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study). Hepatology International, 2022, 16, 59-67.	1.9	5
4	Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alphaâ€fetoprotein levels. Cancer Medicine, 2022, 11, 104-116.	1.3	7
5	Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. World Journal of Gastroenterology, 2022, 28, 140-153.	1.4	6
6	Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. World Journal of Gastroenterology, 2022, 28, 263-274.	1.4	10
7	Itemization difference of patient-reported outcome in patients with chronic liver disease. PLoS ONE, 2022, 17, e0264348.	1.1	2
8	Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients. Cancers, 2022, 14, 2023.	1.7	3
9	Galectin-1 orchestrates an inflammatory tumor-stroma crosstalk in hepatoma by enhancing TNFR1 protein stability and signaling in carcinoma-associated fibroblasts. Oncogene, 2022, 41, 3011-3023.	2.6	14
10	Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuan, a hyperendemic area of southern Taiwan. Kaohsiung Journal of Medical Sciences, 2022, , .	0.8	2
11	Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy. Kaohsiung Journal of Medical Sciences, 2021, 37, 145-153.	0.8	8
12	Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. Journal of the Formosan Medical Association, 2021, 120, 303-310.	0.8	8
13	Exosomeâ€derived differentiation antagonizing nonâ€protein coding RNA with risk of hepatitis C virusâ€related hepatocellular carcinoma recurrence. Liver International, 2021, 41, 956-968.	1.9	17
14	Realâ€world effectiveness of directâ€acting antiviral agents for chronic hepatitis C patients with genotypeâ€2 infection after completed treatment. Kaohsiung Journal of Medical Sciences, 2021, 37, 334-345.	0.8	3
15	Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. Clinical and Molecular Hepatology, 2021, 27, 186-196.	4.5	9
16	Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals. PLoS ONE, 2021, 16, e0245479.	1.1	5
17	Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwanâ€”the Formosaâ€Like Group. Journal of Viral Hepatitis, 2021, 28, 719-727.	1.0	5
18	Genotype distribution, clinical characteristics, and racial differences observed in chronic hepatitis C patients in Pingtung, Taiwan. Journal of the Chinese Medical Association, 2021, 84, 255-260.	0.6	6

#	Article	IF	Citations
19	Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma. Kaohsiung Journal of Medical Sciences, 2021, 37, 616-623.	0.8	8
20	Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan. BMJ Open, 2021, 11, e042861.	0.8	10
21	Comorbidities in patients with chronic hepatitis C and hepatitis B on hemodialysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2261-2269.	1.4	2
22	Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan. Scientific Reports, 2021, 11, 8554.	1.6	11
23	Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. Scientific Reports, 2021, 11, 8184.	1.6	17
24	Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection. PLoS ONE, 2021, 16, e0254028.	1.1	6
25	Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A communityâ€based cohort study. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 3239-3246.	1.4	0
26	First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. Hepatology International, 2021, 15, 1136-1147.	1.9	23
27	Scaling up the in-hospital hepatitis C virus care cascade in Taiwan. Clinical and Molecular Hepatology, 2021, 27, 136-143.	4.5	32
28	The Persistence of Hepatitis C Virus Infection in Hepatocytes Promotes Hepatocellular Carcinoma Progression by Pro-Inflammatory Interluekin-8 Expression. Biomedicines, 2021, 9, 1446.	1.4	3
29	Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 151-156.	1.4	6
30	Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 473-481.	1.4	7
31	Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C. Digestive Diseases and Sciences, 2020, 65, 2120-2129.	1.1	13
32	Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C. International Journal of Molecular Sciences, 2020, 21, 4945.	1.8	9
33	Cure or curd: Modification of lipid profiles and cardioâ€cerebrovascular events after hepatitis C virus eradication. Kaohsiung Journal of Medical Sciences, 2020, 36, 920-928.	0.8	20
34	Viral Interference Between Dengue Virus and Hepatitis C Virus Infections. Open Forum Infectious Diseases, 2020, 7, ofaa272.	0.4	4
35	Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodules. Kaohsiung Journal of Medical Sciences, 2020, 36, 460-466.	0.8	3
36	Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. Journal of Hepatology, 2020, 73, 62-71.	1.8	60

#	Article	IF	Citations
37	Primary cultures of aspiration residual specimens predict outcomes of hepatocellular carcinoma patients receiving curative treatment. Kaohsiung Journal of Medical Sciences, 2020, 36, 750-756.	0.8	2
38	Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1886-1892.	1.4	8
39	The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C. PLoS ONE, 2020, 15, e0242601.	1.1	5
40	Association of serial serum major histocompatibility complex class I chainâ€related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 249-255.	1.4	10
41	Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. PLoS ONE, 2019, 14, e0220663.	1.1	15
42	The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment. Kaohsiung Journal of Medical Sciences, 2019, 35, 624-632.	0.8	8
43	Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study. BMJ Open, 2019, 9, e026703.	0.8	17
44	Elevated interleukin-4 levels predicted advanced fibrosis in chronic hepatitis C. Journal of the Chinese Medical Association, 2019, 82, 277-281.	0.6	5
45	Elevated serum ferritin level associated with hepatic steatosis and fibrosis in hepatitis C virusâ€“infected patients. Journal of the Chinese Medical Association, 2019, 82, 99-104.	0.6	12
46	The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis. Medicine (United States), 2019, 98, e15066.	0.4	8
47	Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients. Journal of Infectious Diseases, 2019, 219, 1224-1233.	1.9	15
48	Fulminant Emphysematous Pancreatic Pseudocyst: Infected with Normal Skin Flora. American Journal of Medicine, 2019, 132, e41-e42.	0.6	0
49	The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C. Journal of the Formosan Medical Association, 2018, 117, 14-23.	0.8	6
50	Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort. Journal of the Formosan Medical Association, 2018, 117, 54-62.	0.8	3
51	Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1Âinfection after liver transplantation: Real-world experience. Journal of the Formosan Medical Association, 2018, 117, 518-526.	0.8	15
52	Interference of hepatitis B virus dual infection in platelet count recovery in chronic hepatitis C patients with curative antiviral therapy. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1108-1114.	1.4	6
53	Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals. Hepatology International, 2018, 12, 544-551.	1.9	14
54	Association of hyperuricemia with disease severity in chronic hepatitis C patients. PLoS ONE, 2018, 13, e0207043.	1.1	13

#	Article	IF	Citations
55	The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C. Oncotarget, 2018, 9, 21313-21321.	0.8	10
56	Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection. Scientific Reports, 2018, 8, 15821.	1.6	6
57	Tolloid-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals. Scientific Reports, 2018, 8, 15058.	1.6	5
58	Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C. Oncotarget, 2018, 9, 12240-12249.	0.8	5
59	A realâ€world impact of costâ€effectiveness of pegylated interferon/ribavarin regimens on treatmentâ€naÃ¯ve chronic hepatitis C patients in Taiwan. Kaohsiung Journal of Medical Sciences, 2017, 33, 44-49.	0.8	11
60	Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment. EBioMedicine, 2017, 15, 81-89.	2.7	30
61	25â€Hydroxy vitamin D suppresses hepatitis C virus replication and contributes to rapid virological response of treatment efficacy. Hepatology Research, 2017, 47, 1383-1389.	1.8	16
62	Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1754-1762.	1.4	59
63	Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection. Kaohsiung Journal of Medical Sciences, 2017, 33, 284-289.	0.8	2
64	Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients. Biomedicine and Pharmacotherapy, 2017, 86, 27-31.	2.5	5
65	The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferonâ€free direct antiviral agents. Kaohsiung Journal of Medical Sciences, 2017, 33, 567-571.	0.8	25
66	Serum Wisteria floribunda agglutininâ€positive Macâ€2â€binding protein expression predicts disease severity in chronic hepatitis C patients. Kaohsiung Journal of Medical Sciences, 2017, 33, 394-399.	0.8	9
67	Interactive effects between Lymphotoxin Î± +252 polymorphism and habits of substance use on risk of hepatocellular carcinoma. Kaohsiung Journal of Medical Sciences, 2017, 33, 334-338.	0.8	2
68	Independent and additive interaction between polymorphisms of tumor necrosis factor Î±â^'308 and lymphotoxin Î±+252 on risk of hepatocellular carcinoma related to hepatitis B. Kaohsiung Journal of Medical Sciences, 2017, 33, 453-457.	0.8	3
69	Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment. Clinical Cancer Research, 2017, 23, 1690-1697.	3.2	32
70	Disease severity and erythropoiesis in chronic hepatitis C. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 864-869.	1.4	4
71	Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients. PLoS ONE, 2017, 12, e0178883.	1.1	18
72	The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma. PLoS ONE, 2017, 12, e0184878.	1.1	5

#	Article	IF	Citations
73	Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. Oncotarget, 2017, 8, 43925-43933.	0.8	12
74	Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C. Oncotarget, 2017, 8, 32618-32625.	0.8	6
75	Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Scientific Reports, 2016, 6, 22995.	1.6	7
76	The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases. Kaohsiung Journal of Medical Sciences, 2016, 32, 362-366.	0.8	22
77	Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, openâ€label, multicenter study. Kaohsiung Journal of Medical Sciences, 2016, 32, 559-566.	0.8	2
78	Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines. Kaohsiung Journal of Medical Sciences, 2016, 32, 68-73.	0.8	54
79	Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy. Oncotarget, 2016, 7, 61325-61335.	0.8	7
80	The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1768-1774.	1.4	14
81	Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C. Medicine (United States), 2015, 94, e690.	0.4	94
82	Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients. PLoS ONE, 2015, 10, e0139796.	1.1	16
83	Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers. Oncotarget, 2015, 6, 23987-24001.	0.8	51
84	Variable uptake feature of focal nodular hyperplasia in Tcâ€99m phytate hepatic scintigraphy/singleâ€photon emission computed tomographyâ€"A parametric analysis. Kaohsiung Journal of Medical Sciences, 2015, 31, 621-625.	0.8	2
85	Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma. Kaohsiung Journal of Medical Sciences, 2015, 31, 77-82.	0.8	11
86	Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. Journal of Hepatology, 2015, 62, 512-518.	1.8	30
87	PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients. Scientific Reports, 2015, 5, 11901.	1.6	9
88	Clinically acceptable colchicine concentrations have potential for the palliative treatment of human cholangiocarcinoma. Kaohsiung Journal of Medical Sciences, 2015, 31, 229-234.	0.8	12
89	Host and virological characteristics of patients with hepatitis C virus mixed genotype 1 and 2 infection. Kaohsiung Journal of Medical Sciences, 2015, 31, 271-277.	0.8	3
90	Feasibility and efficacy of helical tomotherapy in cirrhotic patients with unresectable hepatocellular carcinoma. World Journal of Surgical Oncology, 2015, 13, 201.	0.8	8

#	Article	IF	Citations
91	Clinical utility of a simple primary culture method in hepatocellular carcinoma patients. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 352-357.	1.4	4
92	Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients. PLoS ONE, 2015, 10, e0122259.	1.1	16
93	Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. Journal of Hepatology, 2014, 61, 67-74.	1.8	110
94	Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection. Antiviral Research, 2014, 105, 135-142.	1.9	16
95	Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy. Hepatology International, 2013, 7, 162-170.	1.9	4
96	The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study. Hepatology International, 2013, 7, 180-187.	1.9	2
97	Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. Life Sciences, 2013, 93, 323-328.	2.0	61
98	Hepatocellular carcinoma cells cause different responses in expressions of cancerâ€promoting genes in different cancerâ€associated fibroblasts. Kaohsiung Journal of Medical Sciences, 2013, 29, 312-318.	0.8	28
99	High therapeutic concentration of prazosin up-regulates angiogenic IL6 and CCL2 genes in hepatocellular carcinoma cells. Biomedicine and Pharmacotherapy, 2012, 66, 583-586.	2.5	7
100	Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells. Biomedicine and Pharmacotherapy, 2012, 66, 525-529.	2.5	83
101	Genes responsible for the characteristics of primary cultured invasive phenotype hepatocellular carcinoma cells. Biomedicine and Pharmacotherapy, 2012, 66, 454-458.	2.5	71
102	Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C. Hepatology International, 2012, 6, 613-619.	1.9	4
103	Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. Antiviral Research, 2012, 93, 239-244.	1.9	44
104	Influence of silibinin on differential expressions of total cytokine genes in human hepatocellular carcinoma cell lines. Biomedicine and Preventive Nutrition, 2011, 1, 91-94.	0.9	2
105	Serial serum VEGFâ€A, angiopoietinâ€2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization. Kaohsiung Journal of Medical Sciences, 2011, 27, 314-322.	0.8	30
106	Risk factors for the leakage of chemotherapeutic agents into systemic circulation after transcatheter arterial chemoembolization of hepatocellular carcinoma. Kaohsiung Journal of Medical Sciences, 2011, 27, 431-436.	0.8	4
107	Potential risk factors for the reactivation of the replication of hepatitis B and C viruses after transcatheter arterial chemoembolization of hepatocellular carcinoma. Kaohsiung Journal of Medical Sciences, 2011, 27, 554-559.	0.8	11
108	Research update for articles published in EJCI in 2009. European Journal of Clinical Investigation, 2011, 41, 1149-1163.	1.7	0

#	Article	IF	Citations
109	Pharmacologic concentrations of ascorbic acid cause diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell lines. Biomedicine and Pharmacotherapy, 2010, 64, 348-351.	2.5	20
110	Pharmacologic concentrations of melatonin have diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell lines. Biomedicine and Pharmacotherapy, 2010, 64, 659-662.	2.5	21
111	Relapsed Acute Pancreatitis as the Initial Presentation of Pancreatic Cancer in a Young Man: A Case Report. Kaohsiung Journal of Medical Sciences, 2010, 26, 448-455.	0.8	9
112	Viral Hepatitis Infections in Southern Taiwan: A Multicenter Communityâ€based Study. Kaohsiung Journal of Medical Sciences, 2010, 26, 461-469.	0.8	100
113	Acute Pancreatitis Complicated with Transient Portal Venous Thrombosis in One Patient with Hepatocellular Carcinoma and Cirrhosis. Kaohsiung Journal of Medical Sciences, 2007, 23, 254-258.	0.8	3
114	Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 398-405.	1.4	9
115	Incidence and clinical significance of spontaneous intrahepatic portosystemic venous shunts detected by sonography in adults without potential cause. Journal of Clinical Ultrasound, 2006, 34, 22-26.	0.4	25
116	Outcome of Chronic Hepatitis C Patients who Required Early Termination of Pegylated Interferon-Î± plus Ribavirin Combination Therapy. Antiviral Therapy, 2006, 11, 1015-1020.	0.6	29
117	Safety of fine-needle aspiration in patients with small hepatocellular carcinoma. Hepatology Research, 2005, 31, 31-35.	1.8	10
118	Clinical application of serum C-reactive protein measurement in the detection of bacterial infection in patients with liver cirrhosis. Kaohsiung Journal of Medical Sciences, 2002, 18, 121-6.	0.8	11
119	Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 636-640.	1.4	56
120	Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. Journal of Medical Virology, 2001, 65, 58-65.	2.5	97
121	Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. , 2001, 65, 58.		1
122	Role of serum Câ€reactive protein as a marker of hepatocellular carcinoma in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 417-421.	1.4	22
123	Clinical Evaluation of the Automated COBAS AMPLICOR HCV MONITOR Test Version 2.0 for Quantifying Serum Hepatitis C Virus RNA and Comparison to the Quantiplex HCV Version 2.0 Test. Journal of Clinical Microbiology, 2000, 38, 2933-2939.	1.8	46
124	Serum alanine aminotransferase level in relation to hepatitis B and C virus infections among blood donors. Liver, 1997, 17, 24-29.	0.1	16
125	Circulating immune complexes in chronic hepatitis C. Journal of Medical Virology, 1995, 46, 12-17.	2.5	22
126	Antibodies to hepatitis E virus among chinese patients with acute hepatitis in Taiwan. Journal of Medical Virology, 1994, 43, 341-344.	2.5	11

#	Article	IF	Citations
127	Hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Chinese: A case-control study. International Journal of Cancer, 1994, 56, 619-621.	2.3	40
128	Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a caseâ€control study. Liver, 1994, 14, 98-102.	0.1	80
129	The role of hepatitis C virus in chronic hepatitis B virus infection. Gastroenterologia Japonica, 1993, 28, 23-27.	0.4	33
130	The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study. Cancer, 1992, 69, 2052-2054.	2.0	116